Vera Therapeutics earnings date
Want to see VERA full AI Analyst Report?
Vera Therapeutics (VERA) Q3 2026 Earnings Report
VERA Q3 2026 EPS Results
- Actual EPS
- -$1.30
- Consensus EPS
- -$1.62
- Beat/Miss
- Beat by +$0.32
- One Year Ago EPS
- -$1.26
VERA Q3 2026 Revenue Results
- Actual Revenue
- $10.28M
- Expected Revenue
- $3.42M
- Beat/Miss
- Beat by +$6.86M
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Vera Therapeutics's next earnings date is estimated for March 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, driven by the successful TRUTAKNA launch, approximately 700 patient start forms, robust ORIGIN 3 efficacy results, favorable safety and treatment persistence, regulatory progress toward full approval, encouraging PIONEER data, and expanding payer access. The main negatives were the increased net loss, higher SG&A and operating cash use, the fact that roughly half of initial revenue represented inventory, the pending status of full approval, and higher local administration reactions.
Vera expects net product revenue to become the primary indicator of progress in addition to quarterly patient start forms; it has received approximately 700 patient start forms since July 7, expects the ASN presentation to be a catalyst for us in Q4, plans to submit a marketing authorization application in the first quarter of 2027, and is advancing toward potential full FDA approval in mid-2027, with potential approvals in other regions to follow. The monthly dose range finding study includes 3 different de novo monthly dose cohorts, a cohort switching from weekly to monthly dosing, and a control weekly cohort, with analysis forthcoming with this quarter and results from the switch cohort in Q2 of 2027; the company expects to open enrollment to children aged 2 to 10 in the future. Vera is on track to meet a goal of 50% of covered lives by the end of the year, expects the ratio of demand to inventory in third-quarter revenue to go much higher for demand in the next quarters, and said up to $350 million remain available under its debt facility, subject to the satisfaction of certain conditions.
- Strong Initial TRUTAKNA Launch DemandFollowing accelerated FDA approval on July 7, Vera received approximately 700 patient start forms through November 5. Management said demand continued at a nice pace after ASN, although it was too early to see an inflection.
- TRUTAKNA Demonstrated Kidney Function BenefitIn the ORIGIN 3 final efficacy analysis, which randomized and dosed 428 adults, all prespecified endpoints were met. At 52 weeks, the placebo-adjusted eGFR change from baseline was 5.6 mL per minute, with eGFR of minus 0.1 mL per minute for TRUTAKNA versus minus 5.7 with placebo. Through 104 weeks, the placebo-adjusted annualized eGFR slope was 5.0 mL per minute per year, with minus 0.6 for TRUTAKNA versus minus 5.6 for placebo.
- Reduced Risk of Kidney Disease ProgressionTRUTAKNA reduced the risk of the composite kidney disease progression endpoint by 76% versus placebo through 104 weeks, with a hazard ratio of 0.24. A sustained eGFR decline of 30% or more occurred in 5% of TRUTAKNA patients versus 18% on placebo, and zero TRUTAKNA patients progressed to dialysis, kidney transplantation, or death versus 7 patients on placebo.
- Proteinuria, Biomarker, and Hematuria ImprovementsAt 52 weeks, the placebo-adjusted reduction in UPCR was 51% and the reduction in galactose-deficient IgA1 was 67%; hematuria resolved in 81% of TRUTAKNA-treated patients who had hematuria at baseline. At 104 weeks, the placebo-adjusted UPCR reduction was 60%, and hematuria resolved in 97% of affected TRUTAKNA-treated patients.
- Favorable ORIGIN 3 Safety and Treatment PersistenceOverall adverse events occurred in 75% of TRUTAKNA patients versus 78% on placebo, serious adverse events occurred in 7% versus 15%, and adverse events leading to discontinuation occurred in 2% versus 10%. There were no opportunistic infections, no clinically relevant hypogammaglobulinemia, and no deaths in the TRUTAKNA group. Treatment persistence was 93% for TRUTAKNA versus 79% for placebo.
- Full Approval Regulatory ProgressVera submitted a supplemental biologics licensing application to the FDA seeking full approval of TRUTAKNA in adults with primary IgA nephropathy, based on the ORIGIN 3 final efficacy analysis. The company anticipates potential full FDA approval in mid-2027 and plans to submit a marketing authorization application in Europe in the first quarter of 2027.
- Expansion of Atacicept Development ProgramVera is advancing the Phase II PIONEER basket trial in broader IgA nephropathy populations and other antibody-mediated kidney diseases, as well as a once-monthly dose range-finding study. The company said the integrated program is intended to expand atacicept to additional patient populations and autoimmune kidney diseases.
- Encouraging PIONEER IgA Nephropathy ResultsIn the PIONEER IgA nephropathy cohorts, which enrolled 101 adults including patients with eGFR as low as 20 mL per minute, proteinuria was reduced by 52% from baseline at week 24. Reductions were consistent across cohorts with low baseline eGFR, low baseline proteinuria, and IgA vasculitis with nephritis.
- Initial Membranous Nephropathy FindingsThe PIONEER primary membranous nephropathy cohort enrolled 16 adults with anti-PLA2R-positive disease, most of whom had nephrotic-range proteinuria. Reductions in anti-PLA2R antibody levels were detectable as early as week 4, and proteinuria declined over the first 12 weeks of treatment. No adverse events led to discontinuation and there were no opportunistic infections in the interim analysis.
- Broader Patient Adoption and Prescriber ReachThe approximately 700 patient start forms were not driven by a small cohort of physicians, and management said it felt good about prescriber breadth. Patients with more than 1 gram and less than 1 gram of protein were being prescribed TRUTAKNA, representing a broad mix. Sales efforts are focused on high-decile physicians, including physicians in deciles 8, 9, and 10, as well as academic centers.
- Commercial Execution and At-Home Dosing AppealVera reported more than 29,000 sales calls to date. Management said many patients value once-weekly self-administration at home with a small-volume autoinjector, while physicians value the flexibility of weekly dosing if an adjustment is needed based on clinical judgment.
- Progress in Patient Access and Payer CoverageVera said payer coverage policies were taking shape and that it was on track to reach 50% of covered lives by the end of the year. TRUTAKNA Tru Support provides benefit verification, prior authorization, appeals support, and financial assistance connections. Eligible commercially insured patients may pay as little as $0 out of pocket through copay assistance, while eligible uninsured or underinsured patients may receive TRUTAKNA at no cost.
- Commercial Revenue and Financial FlexibilityNet product revenue from TRUTAKNA was $10.3 million in the third quarter, the first partial quarter of commercial sales. Vera had $384 million in cash equivalents and marketable securities as of September 30, 2026, drew $75 million on its debt facility in late October, and had up to $350 million remaining available under the facility subject to certain conditions. On a pro forma basis reflecting the October borrowing, cash, cash equivalents, and marketable securities would have been $459 million.
- Pediatric and Monthly-Dosing DevelopmentThe PIONEER pediatric IgA nephropathy trial is enrolling children aged 10 and older, with plans to open enrollment to children aged 2 to 10 in the future. The monthly dose range-finding study includes three de novo monthly dose cohorts, a cohort switching from weekly to monthly dosing, and a control weekly cohort; data from the de novo cohorts are expected to be analyzed later in the quarter, with switch-cohort results expected in the second quarter of 2027.
VERA Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 25, 2027 | 2027 (Q4) | -1.34- | -1.39 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -1.62-1.30 | -1.26 | -3.17% (-0.04) | |
| Aug 10, 2026 | 2026 (Q2) | -1.58-1.52 | -1.2 | -26.67% (-0.32) | |
| May 07, 2026 | 2026 (Q1) | -1.33-1.69 | -0.81 | -108.64% (-0.88) | |
| Feb 26, 2026 | 2026 (Q4) | -1.32-1.39 | -0.72 | -93.06% (-0.67) | |
| Nov 05, 2025 | 2025 (Q3) | -1.16-1.26 | -0.85 | -48.24% (-0.41) | |
| Aug 05, 2025 | 2025 (Q2) | -0.82-1.20 | -0.62 | -93.55% (-0.58) | |
| May 06, 2025 | 2025 (Q1) | -0.74-0.81 | -0.56 | -44.64% (-0.25) | |
| Feb 26, 2025 | 2024 (Q4) | -0.81-0.72 | -0.54 | -33.33% (-0.18) | |
| Nov 07, 2024 | 2024 (Q3) | -0.64-0.85 | -0.45 | -88.89% (-0.40) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

